Abstract We isolated a cDNA clone encoding the human prostaglandin (PG) E receptor EP 4 subtype and examined the gene expression in human blood cells. Northern blot analysis revealed that the EP 4 gene is expressed at a high level in peripheral blood mononuclear cells, and at lower levels in cultured human blood cell lines, THP-1 and U937 (monocytoid cell lines), MOLT-4 and Jurkat (T-cell lines), and Raji (B-cell line). To examine regulation of the EP 4 gene expression in the immune system, we studied the effects of phorbol 12-myristate 13-acetate (PMA) on these cell lines. Gene expression was upregulated in THP-1, U937, and Raji cells by PMA, and was downregulated in MOLT-4 and Jurkat cells. In THP-1 cells the effects of PMA were further analyzed, and the upregulation of the EP 4 gene was shown to be followed by an increase in PGE 2 binding sites and in PGE 2 -induced cAMP accumulation. In the striking contrast, other PGE receptor subtypes (EP 1 , EP 2 and EP 3 ) and other prostanoid receptors (IP and DP) were shown not to be upregulated by PMA. Therefore, this is the first demonstration of a highly specific upregulation of the EP 4 subtype in THP-1 cells treated with PMA, suggesting the importance of the EP 4 subtype in the immune system. In the present study we also clarified that EP 4 gene expression is regulated differently among human monocytoid and lymphoid lineage cells, thus leading to the better understanding of the regulatory mecha- 
Introduction
Prostaglandin (PG) E 2 is produced in a wide variety of tissues and exerts a broad spectrum of biological actions by binding to its specific cell surface receptors [1] . There are at least four subtypes of PGE receptor, designated EP 1 , EP 2 , EP 3 , and EP 4 , based upon their pharmacological profiles and signal transduction pathways. Molecular cloning studies of these four subtypes have revealed that they all have seven transmembrane domains and belong to the G protein coupled receptor superfamily [1] . The EP 4 subtype mediates the action of PGE 2 by increasing the intracellular cAMP level, which is inhibited by a subtype-specific antagonist, AH23848B [2] .
The immune system, especially macrophage and lymphocyte, is one of the most important targets of PGE 2 , in which both stimulatory and inhibitory effects of PGE 2 are known [3] ; PGE 2 stimulates IgE and IgG1 production in B cells [4] , while it inhibits tumor necrosis factor-α production in macrophages [5] and interleukin-2 and interferon-γ production in T cells [6] . Theses biological actions of PGE 2 in the immune system are associated mostly with the elevation of the intracellular cAMP levels [3, 4, 6] , suggesting the involvement of the EP 4 subtype. However, the precise subtype(s) which mediates the actions of PGE 2 in the immune system remains to be elucidated.
In this context, in the present study we isolated a fulllength cDNA clone encoding the human PGE receptor EP 4 subtype and examined the gene expression in human peripheral blood mononuclear cells (PBMC) and monocytoid and lymphoid lineage cells. To explore the regulatory mechanisms of the EP 4 subtype gene expression in the immune system, we also studied the EP 4 subtype gene regulations in monocytoid and lymphoid cell lines in response to phorbol 12-myristate 13-acetate (PMA), which activates protein kinase C [7] . 
Materials and methods

Reagents
Cell culture
Human blood cell lines, THP-1, U937, MOLT-4, Jurkat, and Raji, were cultured in RPMI 1640 (Gibco BRL, Grand Island, N.Y) with 2 mM L-glutamine. Culture medium was supplemented with 10% heat-inactivated fetal bovine serum (Sigma), 100 U/ml penicillin-G, and 100 µg/ml streptomycin. Medium was changed 20 h before each experiment and unchanged thereafter to minimize the effects of serum.
Molecular cloning
A cDNA clone encoding the human PGE receptor EP 4 subtype was isolated as previously described [8] from a human lung cDNA library (Clontech, Palo Alto, Calif.) using mouse EP 4 cDNA as a probe [9, 10] . Nucleotide sequences were determined by the dideoxy-chain termination method.
Ligand binding assay
The cloned cDNA was transiently expressed in COS-7 cells as previously described [8] . [ 3 H]PGE 2 binding to the cell membrane of COS-7 cells or THP-1 cells was determined as previously described [10] . The crude membrane was prepared by differential centrifugation by 800 g for 10 min and 100,000 g for 30 min. Pellets were suspended in 20 mM HEPES-NaOH (pH 7.4) containing 10 mM MgCl 2 , and 1 mM EDTA. The crude membrane (40 µg protein) was incubated at 30°C for 1 h with 4 nM (in displacement experiments) or various concentrations (in Scatchard analysis) of [ 3 H]PGE 2 and unlabeled ligands. Nonspecific binding was determined by adding 1000-fold excess of unlabeled PGE 2 to the incubation mixture, and the specific binding was calculated by subtracting nonspecific binding from total binding.
Measurement of cAMP level
After preincubation at 37°C for 10 min in 500 µl of the culture medium containing 500 µM 3-isobutyl-1-methylxanthine (Nacalai Tesque) and 0.1% (w/v) bovine serum albumin (Sigma), 1×10 5 cells were incubated at 37°C for 30 min with PGE 2 , PGD2, or iloprost. The reaction was stopped by adding 500 µl of 12% (w/v) trichloroacetic acid, and the cAMP levels were measured by a radioimmunoassay kit (Yamasa, Tokyo, Japan).
RNA extraction and northern blot analysis PBMC were isolated by the density gradient centrifugation using Ficoll-Paque (Pharmacia, Uppsala, Sweden), and further divided into T-cell-rich fraction and non-T-cell fraction by rosetting with sheep erythrocytes. The present study was conducted with informed consent and approved by the ethical committee on human research of Kyoto University (no. 61-98). Total RNA was extracted by the guanidinium thiocyanate-cesium chloride method [11] from PBMC or cultured human blood cell lines. Northern blot analysis was performed as previously described [8] using the human EP 4 subtype cDNA fragment (nucleotide number -386 to +1653) or the human EP 2 subtype cDNA fragment (nucleotide number +740 to +1107, obtained by reverse transcription PCR with RNA extracted from human PBMC [12] ). The EP 4 subtype mRNA level in the PBMC of a healthy donor was arbitrarily defined as 100 U. The relative mRNA levels of other samples were normalized by the 28S ribosomal RNA levels to correct for the differences in the amount of RNA applied.
Statistics
Statistical analyses were performed using analysis of variance, and P<0.05 was considered as statistically significant.
Results
Molecular cloning and binding characteristics of the human EP 4 subtype
We recently identified the PGE receptor subtype termed EP 2 as the EP 4 subtype in mice [10] . The human EP 4 subtype has been cloned [13, 14] [2, 10] . The cDNA sequences for this receptor reported by An et al. [13] and Bastien et al. [14] differed slightly at nucleotide and amino acid levels. The cDNA sequence of ours (GenBank accession number D28472) was identical with that of Bastien et al.
The human EP 4 subtype gene expression in blood cells and effects of PMA
Northern blot analysis revealed that the EP 4 subtype gene is expressed at a high level in PBMC, and that both the T-cell-rich fraction and non-T-cell fraction express the gene at similar levels (Fig. 1) . The gene expression was observed at lower levels in human blood cell lines; THP-1 and U937 (monocytoid cell lines), MOLT-4 and Jurkat (T-cell lines), and Raji (B-cell line). We also examined the effects of PMA on the EP 4 subtype gene expression in these human cell lines. As shown in Fig. 1 (Fig. 2A) . When treated with 10 nM of PMA, the EP 4 subtype mRNA level significantly increased in 30 min (P<0.01), reached the maximum in 3 h, and sustained it for up to 24 h (five-fold higher than the initial level). PMA treatment for 3 h at concentrations of 1-100 nM increased the mRNA level dose-dependently (significant at all concentrations compared with the untreated level, P<0.05; Fig. 2B ). On the other hand, no significant amounts of the EP 2 subtype mRNA were present in all conditions examined (data not shown). (Fig. 3A) . This K d was consistent with that of the human EP 4 subtype [13] . Treatment with 10 nM of PMA for 24 h increased the PGE 2 binding sites by 4.8-fold, while no appreciable change was noted in the K d value. By contrast, 1 µM of sulprostone (a potent agonist for the EP 1 and EP 3 subtypes) did not displace the [ 3 H]PGE 2 binding to the PMA-treated THP-1 cells (Fig. 3B) .
Furthermore, treatment with 10 nM of PMA for 24 h enhanced the PGE 2 -induced cAMP accumulation by 8.4-fold when 1 µM PGE 2 was added. In contrast, neither iloprost (a stable PGI 2 analogue) nor PGD 2 -induced cAMP accumulation was influenced by PMA (Fig. 4) .
Discussion
The present study demonstrated the EP 4 subtype to be expressed abundantly in PBMC and human blood cell lines. The EP 4 mRNA level was much higher in PBMC than in cultured blood cell lines, and the gene expression was regulated differently by PMA in each cell line. These results suggest the physiological and pathophysiological significances of the EP 4 subtype in the immune system in humans. PMA treatment is known to induce differentiation of THP-1 cells from monocytoid to macrophage-like cells [15] , which is associated with increased PGE 2 production [16] . Upregulation of EP 4 gene expression in THP-1 cells is detected as early as 30 min after PMA treatment, while the increase in PGH synthase-1 mRNA level is detected later than 2 h of treatment [17] and the production of PGE 2 is maximal 24-48 h after treatment [16] . These time courses suggest that upregulation of EP 4 gene expression is not caused by PGE 2 . Further studies are necessary to elucidate the mechanism for the rapid regulation of the EP 4 gene expression.
In the present study augmentation of the EP 4 mRNA level in PMA-treated THP-1 cells was followed by the increase in the PGE 2 binding sites without significant change in K d . Moreover, in PMA-treated THP-1 cells PGE 2 induced significantly higher levels of cAMP accumulation than in untreated THP-1 cells. These results suggest that the augmented response to PGE 2 in PMAtreated THP-1 cells was due not to the alteration of the ligand binding affinity but to the increase in the EP 4 subtype production. Furthermore, we could detect only little or no amounts of the EP 1 , EP 2 , and EP 3 subtypes or the IP (PGI 2 receptor) and DP receptors (PGD 2 receptor) in PMA-treated THP-1 cells. These results indicate that none of the EP 1 , EP 2 , EP 3 , IP, and DP receptors but the EP 4 subtype alone is responsible for PGE 2 -induced cAMP accumulation in PMA-treated THP-1 cells, and that the EP 4 subtype is specifically upregulated by PMA in THP-1 cells.
In conclusion, the present study demonstrates that EP 4 gene expression is regulated differently among human monocytoid and lymphoid lineage cells. This study will facilitate the better understanding of the regulatory mechanisms for the human EP 4 
